Mantle Cell Lymphoma - 23 Studies Found Completed : Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma : Mantle Cell Lymphoma Recurrent : 2011-03-24 : Drug: Combination of Bortezomib, Fludarabine and Cyclophosphamide bortezomib 1.3mg/m^2 i.v. on days 1, 4 Withdrawn : A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2016-04-08 : Drug: acalabrutinib Drug: ibrutinib Active, not recruiting : A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2013-01-24 : Drug: Bendamustine 90 mg/m2 ad Recruiting : Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2015-02-02 : Drug: Ibrutinib NOT_YET_RECRUITING : Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma : : 2024-11-23 : Undergo biopsy RECRUITING : Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2024-11-23 : Given PO RECRUITING : Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma : Blastoid Variant Mantle Cell Lymphoma : 2024-11-23 : Undergo tumor biopsy NOT_YET_RECRUITING : A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na�ve Mantle Cell Lymphoma : Mantle Cell Lymphoma (MCL) : 2024-11-23 : Investigational Product RECRUITING : A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2024-11-23 : Participants will receive treatment with intravenous tafasitamab and oral lenalidomide for up to 12 cycles.Each cycle is 28 days in length. NOT_YET_RECRUITING : Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2024-11-23 : Given PO <<< Previous | Next >>>
